Daewon Pharmaceutical Co., Ltd. (KRX:003220)

Daewon Pharmaceutical Revenue

Daewon Pharmaceutical had revenue of 152.83B KRW in the quarter ending June 30, 2026, with 6.24% growth. This brings the company's total for the last twelve months to 614.64B, up 1.83% year-over-year. In the year 2025, Daewon Pharmaceutical had annual revenue of 605.43B with 1.22% growth. That makes Daewon Pharmaceutical the 11,728th largest company in the world by revenue and 556th in South Korea.

• Revenue (ttm): 614.64B
• Revenue Growth: +1.83%
• P/S Ratio: 0.28
• Revenue / Employee: 497.28M
• Employees: 1,236
• Market Cap: 172.11B

Revenue Chart

Chart

Chart

Revenue by Segment

By Segment

Chart

• Pharmaceuticals 542.98B 89.1%
• Health Functional Food 36.07B 5.9%
• Cosmetics 30.07B 4.9%
• Other Sectors 481.72M 0.1%

By Geography

Chart

• South Korea 584.75B 96.6%
• Foreign 20.68B 3.4%

Fiscal year ended Dec 31, 2025 See the full Daewon Pharmaceutical breakdown

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	605.43B	7.27B	1.22%
Dec 31, 2024	598.16B	71.21B	13.51%
Dec 31, 2023	526.95B	48.07B	10.04%
Dec 31, 2022	478.88B	124.71B	35.21%
Dec 31, 2021	354.18B	45.68B	14.81%

Data Source: S&P Global Market Intelligence Last updated: Aug 7, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Nov 3, 2026

Data Sources Report a data error